A-shares fluctuate | Three-child Policy stocks rise. Government work report: formulate policies to promote childbirth and issue childcare subsidies.

On March 5, Gelonghui reported that A-shares of companies related to the Three-child Policy experienced significant increases, with Cabio Biotech(Wuhan) rising over 6%, Jinfa Labi Maternity & Baby Articles rising over 5%, Shanghai Aiyingshi rising over 4%, and Beingmate Co., Ltd., Kidswant, Everjoy Health Group, and Jianmin Pharmaceutical Group seeing gains as well. In news, the government work report stated that policies to promote childbirth will be formulated, childcare subsidies will be issued, integrated childcare services will be vigorously developed, and the supply of inclusive childcare services will be increased. Additionally, the General Office of the State Council issued measures in October of last year regarding accelerating the improvement of the fertility support policy system to promote the construction of a fertility-friendly society, mentioning support for childbirth from four aspects, including strengthening childbirth service support and enhancing the early childhood service system.

Gelonghui Finance10:03

The trade price is 0.831 billion yuan! Cabio Biotech(Wuhan) disclosed the latest restructuring plan: it intends to reduce one trading counterpart and raise 0.269 billion yuan through a private placement.

① Both parties signed a performance commitment, promising that the Net income of Ouyi Biotech will not be less than 0.27 billion yuan in total for the fiscal years 2025, 2026, and 2027; ② The profits of Cabio Biotech(Wuhan) are expected to further increase. The company estimates that its revenue for the first three quarters of 2024 will rise from 0.387 billion yuan before the Trade to 0.655 billion yuan; the Net income attributable to the parent company will increase from 83.8902 million yuan to 0.113 billion yuan.

cls.cn08:47

Cabio Biotech(Wuhan) (688089.SH): intends to purchase 63.2134% of the equity in Ouyi Biology.

On March 4, Gelonghui reported that Cabio Biotech(Wuhan) (688089.SH) announced that the listed company plans to purchase 63.2134% equity of Ouyi Biotech from 13 trading parties including Wang Shuwei, Dong Dong, Xiao Yunping, Wang Xiuping, Jin Chao, Shi Xianjun, Shanghai Fanyi, Ningbo Ruiou, Ningbo Ourun, China National Pharmaceutical Phase II, Nantong Dongzheng, Suzhou Dingshi, and Shanghai Shengqi by issuing shares and paying cash, raising matching funds, with a transaction price of 830.6237 million yuan. Before this transaction, the listed company is based on Biotechnology, with synthetic biology as the underlying technology, using cell factories as the preparation method, through sustainable.

Gelonghui FinanceMar 4 20:08

Express News | Cabio Biotech(Wuhan): plans to acquire 63.2134% of the shares of Ouyi Biotechnology at a transaction price of 0.831 billion yuan.

BreakingsMar 4 20:01

Cabio Biotech(Wuhan) (688089): Excellent performance in Q4, focus on acquisition progress.

Event: The company announced the performance forecast for 2024. In 2024, the company achieved revenue of 0.555 billion yuan, +25.06% year-on-year; the net income attributable to the parent company was 0.124 billion yuan, +35.25% year-on-year; the non-recurring net income attributable to the parent company.

China Securities.Feb 28 07:37

Jiabiyou: Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Performance Report Announcement

SZSIFeb 28 00:00 · Announcements